Front Row Advisors LLC Cara Therapeutics, Inc. Transaction History
Front Row Advisors LLC
- $271 Million
- Q3 2024
A detailed history of Front Row Advisors LLC transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Front Row Advisors LLC holds 80 shares of CARA stock, worth $21. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80
Previous 80
-0.0%
Holding current value
$21
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CARA
# of Institutions
74Shares Held
12.8MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA2.25MShares$607,2050.0% of portfolio
-
Chescapmanager LLC Baltimore, MD1.7MShares$459,5690.06% of portfolio
-
Farallon Capital Management LLC San Francisco, CA1.56MShares$420,1870.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN1.11MShares$300,5210.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.11MShares$299,4110.0% of portfolio
About Cara Therapeutics, Inc.
- Ticker CARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,725,900
- Market Cap $14.5M
- Description
- Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...